Prevenção Quaternária e limites em medicina*,**

Autores

  • Marc Jamoulle Espace Temps maison de santé, Charleroi, family doctor, investigador em Cuidados Primários. Departement Universitiare de Médecine Générale of the Université de Liège (DUMG ULg).
  • Luís Filipe Gomes Universidade do Algarve (UAlg). Faro,

DOI:

https://doi.org/10.5712/rbmfc9(31)867

Palavras-chave:

Conflito de Interesses, Medicalização, Prevenção Quaternária, Medicina de Família e Comunidade

Resumo

O conceito de Prevenção Quaternária, um questionamento sobre a base da ação médica, nasceu na articulação da relação médico-paciente. Refere-se a toda a atividade médica, sendo uma importante ferramenta para a medicina de família. É uma interrogação ética sobre os excessos da demasiada e demasiadamente pouca medicina e fornece algumas respostas.

Downloads

Não há dados estatísticos.

Métricas

Carregando Métricas ...

Biografia do Autor

Marc Jamoulle, Espace Temps maison de santé, Charleroi, family doctor, investigador em Cuidados Primários. Departement Universitiare de Médecine Générale of the Université de Liège (DUMG ULg).

Family Practitioner. Health data management specialist.

Referências

World Psychiatric Association. A conceptual framework for the revision of the ICD-10 classification of mental and behavioural disorders. World Psychiatry. 2011;10(2):86-92. PMid:21633677 PMCid:PMC3104876. DOI: https://doi.org/10.1002/j.2051-5545.2011.tb00022.x

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: APA; 2013. DOI: https://doi.org/10.1176/appi.books.9780890425596

Cosgrove L, Wheeler EE. Drug firms, the codification of diagnostic categories, and bias in clinical guidelines. J Law Med Ethics [Internet]. 2013;14(3):1-27. Disponível em: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2286724

St-Onge JC. Tous fous? L’influence de l’industrie pharmaceutique sur la psychiatrie. Montréal: Ecosociété; 2013.

Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. Br Med J. 2002;324(7342):886-891. http://dx.doi.org/10.1136/bmj.324.7342.886 DOI: https://doi.org/10.1136/bmj.324.7342.886

Fugh-Berman A, Ahari S. Following the script: how drug reps make friends and influence doctors. PLoS Med. 2007;4(4):e150. PMid:17455991 PMCid:PMC1876413. http://dx.plos.org/10.1371/journal.pmed.0040150 DOI: https://doi.org/10.1371/journal.pmed.0040150

Mintzes B, Lexchin J, Sutherland JM, Beaulieu MD, Wilkes MS, Durrieu G, et al. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States. J Gen Intern Med. 2013;10:1368-1375. PMid:23558775. http://dx.doi.org/10.1007/s11606-013-2411-7 DOI: https://doi.org/10.1007/s11606-013-2411-7

Sah S, Fugh-Berman A. Physicians under the influence: social psychology and industry marketing strategies. J Law Med Ethics [Internet]. 2013;14(3):1-27. Disponível em: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2286433

Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Smith GD, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1. http://dx.doi.org/10.1002/14651858.CD004816.pub5 DOI: https://doi.org/10.1002/14651858.CD004816.pub5

Cathébras P. [Doctor Knock lives at Wall Street. The new targets of pharmaceutical industry]. Rev Med Interne. 2003;24(8):538-41. PMid:12888175. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/12888175 DOI: https://doi.org/10.1016/S0248-8663(03)00195-4

Goldacre B, Bad pharma: how drug companies mislead doctors and harm patients. London: Faber & Faber; 2012

Parry V. The art of branding a condition. Med Mark Media [Internet]. 2003;38(5)43-49 Disponível em: http://www.ybranding.com/Content/pdf/TheArtofBrandingaCondition.pdf.

Heath I. Combating disease mongering: daunting but nonetheless essential. PLoS Medicine. 2006;3(4):e146. PMid:16597174 PMCid:PMC1434491. http://dx.doi.org/10.1371/journal.pmed.0030146 DOI: https://doi.org/10.1371/journal.pmed.0030146

Brownlee S. Overtreated: why too much medicine is making us sicker and poorer. USA: Bloomsbury; 2008.

Light DW, Lexchin J, Darrow JJ. Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs. J Law, Med Ethics. 2013;14(3):590-600. DOI: https://doi.org/10.1111/jlme.12068

Dumit J. Drugs for life. Durham: Duke University Press; 2012. PMCid:PMC3342335. http://dx.doi.org/10.1215/9780822393481 DOI: https://doi.org/10.1215/9780822393481

Welch HG, Schwartzl L, Woloshin S. Overdiagnosed. Boston: Beacon Press; 2011.

Morell Sixto, ME, Martínez González,C, Quintana Gómez, JL. Disease mongering, el lucrativo negocio de la promoción de enfermedades. Rev Pediatr Aten Primaria. 2009;11(43)491-512. http://dx.doi.org/10.4321/S1139-76322009000400011 DOI: https://doi.org/10.4321/S1139-76322009000400011

Moynihan R. A new deal on disease definition. Br Med J. 2011;342:d2548-d2548. PMid:21540259. http://dx.doi.org/10.1136/bmj.d2548 DOI: https://doi.org/10.1136/bmj.d2548

Zahl PH, Gøtzsche PC, Mæhlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol [Internet]. 2011;12(12):1118-1124 [acesso em 2011 Oct 17]. PMid:21996169. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/21996169 DOI: https://doi.org/10.1016/S1470-2045(11)70250-9

Gøtzsche PC, Gotzsche PG. Mammography screening: truth, lies and controversy. Radcliffe Publishing [Internet]; 2012. p. 400. [acesso em 2012 Feb 3]. Disponível em: http://www.radcliffe-oxford.com/books/bookdetail.aspx?ISBN=1846195853

Meador CK. The art and science of non disease. New Engl J Med. 1965;14(272):92-95 http://dx.doi.org/10.1056/NEJM196501142720208 DOI: https://doi.org/10.1056/NEJM196501142720208

Smith R. In search of "non-disease". Br Med J. 2002;324(7342):883-885. http://dx.doi.org/10.1136/bmj.324.7342.883 DOI: https://doi.org/10.1136/bmj.324.7342.883

Barsky AJ, Borus JF. Functional somatic syndromes. Ann Intern Med. 1999;130(11):910-921. http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00016 DOI: https://doi.org/10.7326/0003-4819-130-11-199906010-00016

Jamoulle M. Information et informatisation en médecine générale [Internet]. Belgium: Presses Universitaires de Namur; 1986. p. 193-209. Disponível em: http://www.ph3c.org/PH3C/docs/27/000103/0000405.pdf

Jamoulle M, Roland M. Prévention quaternaire De Wonca world Hong Kong 1995 à Wonca world Prague 2013. Wonca world Prague [Internet]. 2013. Poster. Disponível em: http://www.ph3c.org/PH3C/docs/27/000284/0000440.pdf.

Jamoulle M. A propos d'un dessin. Ethica Clinica [Internet]. 2013;70:28-31. Disponível em: http://www.ph3c.org/PH3C/docs/27/000281/0000416.pdf.

Illich I. Némésis médicale: l'expropriation de la santé. Paris: Seuil; 1975.

Carpentier J. Medical flipper. Paris: La Découverte; 1989. Cahiers libres, 402.

Balint M. The doctor, his patient, and the illness. Edinburgh: Churchill Livingstone; 1964.

McWhinney IR, Freeman T. A Textbook of family medicine. 2th ed. Oxford University Press; 1997.

Jamoulle M. Déclaration d'intention; Le médecin généraliste et de famille et l'usager de drogue [Internet]. 1997. Disponível em: http://www.ulb.ac.be/esp/mfsp/ethitox-fr.html

World Organization of National Colleges - WONCA International Classification Committtee. An international glossary for general/family practice. Fam Pract [Internet]. 1995;12(3):341-369. http://dx.doi.org/10.1093/fampra/12.3.341 DOI: https://doi.org/10.1093/fampra/12.3.341

Jamoulle M, Roland M. Quaternary prevention and the glossary of general practice/family medicine. Hong Kong: WICC; 1995.

Bentzen N. Wonca dictionary of general/family practice. Copenhagen: Wonca International Classification Committtee; 2003.

Downloads

Publicado

2013-12-31

Como Citar

1.
Jamoulle M, Gomes LF. Prevenção Quaternária e limites em medicina*,**. Rev Bras Med Fam Comunidade [Internet]. 31º de dezembro de 2013 [citado 29º de março de 2024];9(31):186-91. Disponível em: https://rbmfc.org.br/rbmfc/article/view/867

Edição

Seção

ENSAIOS

Plaudit